100%ORR!强生CD19/CD20双靶CAR-T疗法Ib期数据首次公布

医药魔方
Jun 14, 2025

6月13日,强生宣布了JNJ-90014496(JNJ-4496)正在进行的Ib期研究的首个临床数据,JNJ-90014496 是一种双靶向抗 CD19/CD20 双特异性自体嵌合抗原受体 (CAR) T 细胞疗法,正在既往未接受过CAR-T细胞疗法治疗的复发或难治性大 B 细胞淋巴瘤(R/R LBCL) 患者中进行研究。研究结果显示了 JNJ-4496 在治疗 R/R LBCL 患者(包括复发或...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10